ON-DEMAND WEBINAR
Method development for characterization of mRNA vaccines and therapeutics with mass photometry
Presenters:
Lauren Barnes – Senior Scientist, Pfizer
Matt Ranaghan – Senior Applications Scientist, Refeyn
Discover how Pfizer and Refeyn are advancing mRNA drug development with mass photometry.
The global pipeline of mRNA therapeutics is expanding rapidly, with hundreds of candidates in development. Thanks to their adaptability and cell-free manufacturing, mRNA-based drugs are poised to become a major class of therapeutics. But as innovation accelerates, so must the analytical tools that ensure these therapies are safe, stable, and effective.
In this on-demand webinar, Lauren Barnes (Senior Scientist, Pfizer) and Matt Ranaghan (Senior Applications Scientist, Refeyn) explore how mass photometry (MP)—a cutting-edge technique that uses light to measure the mass of molecules in solution—is revolutionizing RNA analysis. Learn how MP enables rapid, label-free, single-molecule characterization of mRNA identity, purity, aggregation, and stoichiometry.
What You’ll Learn:
- Why mRNA is reshaping the future of therapeutics
- How mass photometry works and why it matters
- Key experimental considerations for reliable MP data
- How MP supports formulation, process optimization, and quality control in RNA workflows
Whether you’re working in RNA research, drug development, or analytical sciences, this webinar offers valuable insights into how mass photometry is accelerating biological discovery.